分子靶向药物联合TACE在肝癌治疗中的临床研究-影像医学与核医学专业论文.docx

万方数据 万方数据 目 录 中文摘要······························································································· （1） 英文摘要······························································································· （2） 论文题目······························································································· （4） 材料与方法····························································································（5） 结果··································································································· （7） 讨论··································································································· （9） 结论··································································································· （12） 参考文献····························································································· （14） 文献综述····························································································· （18） 参考文献····························································································· （23） 缩略语表····························································································· （25） 攻读学位期间发表文章情况····································································· （27） 个人简历····························································································· （28） 致谢··································································································· （29） 1内蒙古医科大学硕士研究生学位论文（ 1 内蒙古医科大学硕士研究生学位论文（2015） 中文摘要 目 的 探 讨 分 子 靶 向 药 物 联 合 肝 动 脉 栓 塞 化 疗 (Transcatherter arterial chemoembolization，TACE)治疗肝细胞性肝癌（Hepatocellular carcinoma，HCC）的临床 疗效与安全。方法 于 2013 年 12 月至 2014 年 10 月选择符合入组标准的 40 例原发性肝 癌患者作为研究对象。将研究对象应用随机数字表法分为单纯行 TACE 组（对照组，20 例）和 TACE 联合分子靶向药物组（治疗组，20 例）。对照组行单纯的 TACE 手术治疗; 治疗组给予 TACE 的基础上再于导管中灌注恩度 60mg,于术后第 1 天开始连续静滴 10d, 15 mg/d。并于 TACE 术后 10 天后开始口服索拉非尼 400mg, 2 次/d。只在 TACE 术当天 及术后 10 天内不口服索拉菲尼。两组患者 1~2 个月为 1 个疗程,治疗 1~5 个疗程不等。 在治疗 3～6 周进行临床疗效评价，并进行生话质量评价。TACE 术前 4 天及术后 1 周 进行血清甲胎蛋白（